Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Diana Brixner, PhD, and Ashley Peterson, MHA, explore the distinctions between prescription digital therapeutics (PDTs) and wellness mobile apps, addressing the role of insurance coverage and the clinical validation requirements that payers consider when determining whether to cover PDTs as a treatment modality.

Now Viewing

EP: 1.Differentiating PDTs from Wellness Apps and Evaluating Efficacy

EP: 2.Payer Needs and Strategies for Evaluating and Covering PDTs

EP: 3.Payers Review Process and Effective Strategies for PDT Coverage

EP: 4.Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

EP: 5.Dawn of the Age of Adopting PDTs

EP: 6.Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

EP: 7.Evolving Commercialization and Distribution Models for PDTs

EP: 8.Promoting Appropriate PDT Prescribing Through Provider Education and Support

EP: 9.Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

EP: 10.Optimizing Benefit Design and Implementation for Improved PDT Access

EP: 11.PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Related Videos

Related Content

Advertisement

July 26th 2024

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Sabrina Serani

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 26th 2024

Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial

Laura Joszt, MA

The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

Related Content

Advertisement

July 26th 2024

Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors

Sabrina Serani

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 26th 2024

Hemophilia A Gene Therapy Superior to Standard of Care in Phase 3 Trial

Laura Joszt, MA

The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick

In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.